PDCD1 and Recurrent upper respiratory tract infections: We found that the incidence rate of respiratory adverse reactions(cough, pneumonitis, upper respiratory tract infection) in patients receiving combination therapy was higher than that in patients receiving PD-1 or PD-L1 inhibitor monotherapy.